FDA response to HRG
This article was originally published in The Gray Sheet
Executive SummaryFDA's device center defends categorization of five Class II recalls in a May 18 response to Public Citizen's Health Research Group, which had questioned the classification of the recalls in a May 7 letter ("The Gray Sheet" May 17, p. 18). The device center explains that recalls of Infrasonics' Adult Star ventilator, Theratronics' Therac Model 20 (T20) linear accelerator, Gambro Lundia AB's Bicarbonate Control Monitors, Pacific Communication's Central Telemetry Systems for arrhythmia detection and Sarns/3M's MDX battery pack were deemed Class II because the device problems presented low or moderate risk of significant adverse health consequences.
You may also be interested in...
A reagent in a batch of COVID-19 tests shipped by the US Centers for Disease Control and Prevention to state laboratories “wasn’t performing consistently,” a top CDC official says, so the agency is reformulating it – slowing down the labs’ ability to use the diagnostic, which yielded inconsistent results when quality-tested. But waiting in the wings are commercial coronavirus test kits being developed by Qiagen and Cepheid; both firms say they’ll submit the kits to the FDA for emergency-use approval.
OIG will focus on successful drugs that have been repurposed as orphans, noting nine of the 10 top selling drugs have both orphan and non-orphan indications.
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.